RxDoctor Payments Data

Sanjeev Patel, MD

Interventional Cardiology · Saddle Brook, NJNPI 1194803361

Payments from drug & device makers

$9,194in general payments, 2019–2025

Across 141 payments — averaging $65.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$1K
  • Amgen$735
  • Abiomed$570
  • Edwards Lifesciences$555
  • AstraZeneca$545
  • plus $4K from 15 others

What the payments were for

  • Food & beverage$9,11499%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,194 in reported general payments places this provider in the 50th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$190,548
Medicare patients
1,465
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$304,306
XareltoRivaroxaban107$135,328
EntrestoSacubitril/Valsartan75$93,806
JardianceEmpagliflozin47$58,346
Repatha SureclickEvolocumab36$40,527
VerquvoVericiguat15$32,335
MultaqDronedarone Hcl14$26,104
LivaloPitavastatin Calcium17$15,605
Praluent PenAlirocumab19$12,774
Breo ElliptaFluticasone/Vilanterol23$9,170
Nebivolol Hcl90$6,249
Metoprolol Succinate388$6,223
Amiodarone Hcl60$5,620
Ezetimibe134$4,800
Atorvastatin Calcium357$4,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$479$304,306239 claims
Johnson & JohnsonXarelto$250$135,328107 claims
NovartisEntresto$186$93,80675 claims
Boehringer IngelheimJardiance$395$58,34647 claims
MerckVerquvo$101$32,33515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Saddle Brook

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →